European Archives - Page 689 of 1587 - European Medical Journal

Coin stacks

Genentech acquires Regor’s next-gen CKD inhibitor portfolio

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth $850M.

Immune Dysfunction in Severe Paediatric Febrile Illnesses

MRD negativity and clonal diversity in multiple myeloma patients predict better survival, according to a UCSF study using next-gen sequencing.

Asleep Surgery Increases Risk of Oedema in Parkinson's Disease

Researchers have shown that peri-electrode oedema occurs in 40% of Parkinson’s Disease patients after deep brain stimulation, and asleep surgery is the only independent predictive factor for oedema onset.

PREVENT Trial: New Prostate Biopsy Technique Lowers Infection Risk

A new technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches

Novel Sleeve Reduces Skin Damage with Axillary Osmidrosis Surgery

A novel protective sleeve has been shown to significantly reduce skin complications, including bruising and erosion, in patients undergoing surgery for axillary osmidrosis

3D-Printed Intelligent Ostomy Bags Improve Stoma Care

Researchers have shown that 3D-printed, customisable ostomy bags with sensors and stimulators on stoma nursing significantly reduced skin complications

Hyperkalemic Paralysis by Addisonian Crisis: A Near Fatal Accident

This case report presents an unusual clinical scenario where a patient experienced temporary paralysis of his lower limbs while driving…

Orange lungs on yellow background

Sanofi and Regeneron's allergy drug is first biologic for COPD

Sanofi and Regeneron have announced that dupilumab has received an FDA approval in COPD and an eosinophilic phenotype.

Researchers Discover the Best Drug for Migraines

A study has revealed triptans are the most effective medicine for adults experiencing acute migraines – specifically, eletriptan, rizatriptan, sumatriptan, and zolmitriptan.

Risk of Second Primary Malignancies After CAR-T Therapy

A study has raised awareness about the risk of second primary malignancies in patients treated with chimeric antigen receptor T-cell therapy for hematologic cancers